T

ype 1 diabetics, armed with glucose meters and insulin pens, are caught in a delicate high-wire act. Too much glucose wreaks havoc on nerves and blood vessels, while too little causes dizziness and nausea. A Cleveland biotech company is trying to change that by delivering insulin to the liver, where it naturally goes.

Diasome has three phase 2 clinical trials in progress testing nanoparticles known as hepatocyte-directed vesicles. These particles, smaller than the period at the end of this sentence, stick to insulin like Velcro and bring it to the liver. Diasome believes its approach will better manage patients’ blood sugar than administering insulin alone.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

    • Diane, I am a Type 2 Diabetic and are all for promising new therapies. However, I’m also a biochemist and have concerns about targeting the liver directly with insulin. While it is true that insulin delivered to the liver suppresses glucose production, thereby lowering blood glucose levels, that same insulin stimulates the liver to increase triglyceride (fat) production, release these fatty substances into the blood and if present in sufficient quantities these elevated triglyceride levels in the blood can CAUSE insulin resistance, which seems to be somewhat self defeating. This compound needs to get a hard long look from a metabolic basis as it proceeds through clinical trials.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.